Intervontions of Interest:

Monoclonal Antibodies

  • natalizumab (Tysabri®, Biogen)
  • ofatumumab (Kesimpta®, Novartis)
  • ocrelizumab (Ocrevus®, Genentech)
  • rituximab (Rituxan®, Genentech, and biosimilars)
  • ublituximab (TG Therapeutics)

 Oral Therapies

  • dimethyl fumarate (Tecfidera®, Biogen, and generics)
  • diroximel fumarate (Vumerity®, Biogen)
  • monomethyl fumarate (Bafiertam®, Banner Life Sciences)
  • fingolimod (Gilenya®, Novartis)
  • ozanimod (Zeposia®, Bristol Myers Squibb)
  • ponesimod (Ponvory®, Janssen)
  • siponimod (Mayzent®, Novartis)
  • teriflunomide (Aubagio®, Sanofi)

Multiple sclerosis (MS) is a chronic, autoimmune disorder of the central nervous system. characterized by an inflammatory cascade of demyelination and axonal loss, which results in neurologic damage. The exact cause of MS is unknown, but genetic, environmental, and lifestyle factors may contribute to the development of the disease. MS affects more than 900,000 people in the United States (US).Women are affected almost 3 times more than men, and there are racial/ethnic differences in MS prevalence.

For questions, please contact Laura Cianciolo, Program Manager, at lcianciolo@icer.org.

View the Key Stakeholder List.